KEROS THERAPEUTICS INC (KROS) Fundamental Analysis & Valuation

NASDAQ:KROS • US4923271013

Current stock price

12 USD
+0.31 (+2.65%)
At close:
12 USD
0 (0%)
After Hours:

This KROS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. KROS Profitability Analysis

1.1 Basic Checks

  • In the past year KROS was profitable.
  • KROS had a positive operating cash flow in the past year.
  • In the past 5 years KROS reported 4 times negative net income.
  • In the past 5 years KROS reported 4 times negative operating cash flow.
KROS Yearly Net Income VS EBIT VS OCF VS FCFKROS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M

1.2 Ratios

  • KROS has a Return On Assets of 25.74%. This is amongst the best in the industry. KROS outperforms 97.49% of its industry peers.
  • The Return On Equity of KROS (28.70%) is better than 96.71% of its industry peers.
  • With an excellent Return On Invested Capital value of 16.81%, KROS belongs to the best of the industry, outperforming 96.33% of the companies in the same industry.
Industry RankSector Rank
ROA 25.74%
ROE 28.7%
ROIC 16.81%
ROA(3y)-15.34%
ROA(5y)-20.63%
ROE(3y)-16.71%
ROE(5y)-22.4%
ROIC(3y)N/A
ROIC(5y)N/A
KROS Yearly ROA, ROE, ROICKROS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

  • With an excellent Profit Margin value of 35.65%, KROS belongs to the best of the industry, outperforming 96.52% of the companies in the same industry.
  • The Operating Margin of KROS (27.69%) is better than 95.36% of its industry peers.
Industry RankSector Rank
OM 27.69%
PM (TTM) 35.65%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KROS Yearly Profit, Operating, Gross MarginsKROS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -20K -40K -60K -80K -100K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

10

2. KROS Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so KROS is creating value.
  • Compared to 1 year ago, KROS has less shares outstanding
  • KROS has less shares outstanding than it did 5 years ago.
  • KROS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KROS Yearly Shares OutstandingKROS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
KROS Yearly Total Debt VS Total AssetsKROS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • KROS has an Altman-Z score of 4.50. This indicates that KROS is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 4.50, KROS is doing good in the industry, outperforming 72.53% of the companies in the same industry.
  • KROS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.5
ROIC/WACC1.82
WACC9.21%
KROS Yearly LT Debt VS Equity VS FCFKROS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 15.45 indicates that KROS has no problem at all paying its short term obligations.
  • KROS's Current ratio of 15.45 is amongst the best of the industry. KROS outperforms 92.84% of its industry peers.
  • A Quick Ratio of 15.45 indicates that KROS has no problem at all paying its short term obligations.
  • The Quick ratio of KROS (15.45) is better than 92.84% of its industry peers.
Industry RankSector Rank
Current Ratio 15.45
Quick Ratio 15.45
KROS Yearly Current Assets VS Current LiabilitesKROS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. KROS Growth Analysis

3.1 Past

  • KROS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 136.33%, which is quite impressive.
  • KROS shows a strong growth in Revenue. In the last year, the Revenue has grown by 6774.96%.
EPS 1Y (TTM)136.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.56%
Revenue 1Y (TTM)6774.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-87.34%

3.2 Future

  • KROS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -27.32% yearly.
  • The Revenue is expected to decrease by -13.01% on average over the next years. This is quite bad
EPS Next Y-299.03%
EPS Next 2Y-105.12%
EPS Next 3Y-51.27%
EPS Next 5Y-27.32%
Revenue Next Year-99.86%
Revenue Next 2Y-89.36%
Revenue Next 3Y-45.98%
Revenue Next 5Y-13.01%

3.3 Evolution

KROS Yearly Revenue VS EstimatesKROS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
KROS Yearly EPS VS EstimatesKROS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

4

4. KROS Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 6.59, the valuation of KROS can be described as very cheap.
  • 97.49% of the companies in the same industry are more expensive than KROS, based on the Price/Earnings ratio.
  • KROS is valuated cheaply when we compare the Price/Earnings ratio to 25.60, which is the current average of the S&P500 Index.
  • The Forward Price/Earnings Ratio is negative for KROS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 6.59
Fwd PE N/A
KROS Price Earnings VS Forward Price EarningsKROS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of KROS indicates a rather cheap valuation: KROS is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 2.23
EV/EBITDA -0.74
KROS Per share dataKROS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • KROS's earnings are expected to decrease with -51.27% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-105.12%
EPS Next 3Y-51.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KROS Dividend Analysis

5.1 Amount

  • KROS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KROS Fundamentals: All Metrics, Ratios and Statistics

KEROS THERAPEUTICS INC

NASDAQ:KROS (4/2/2026, 8:00:03 PM)

After market: 12 0 (0%)

12

+0.31 (+2.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-04
Earnings (Next)05-04
Inst Owners64.27%
Inst Owner Change-41.13%
Ins Owners1.6%
Ins Owner Change-0.18%
Market Cap236.64M
Revenue(TTM)244.06M
Net Income(TTM)87.01M
Analysts78.67
Price Target23.75 (97.92%)
Short Float %11.18%
Short Ratio4.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)24.52%
Min EPS beat(2)-34.1%
Max EPS beat(2)83.15%
EPS beat(4)3
Avg EPS beat(4)410.93%
Min EPS beat(4)-34.1%
Max EPS beat(4)1560.5%
EPS beat(8)5
Avg EPS beat(8)204.31%
EPS beat(12)8
Avg EPS beat(12)136.59%
EPS beat(16)10
Avg EPS beat(16)103.06%
Revenue beat(2)1
Avg Revenue beat(2)90.82%
Min Revenue beat(2)-86.31%
Max Revenue beat(2)267.96%
Revenue beat(4)3
Avg Revenue beat(4)2527.78%
Min Revenue beat(4)-86.31%
Max Revenue beat(4)9385.68%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.81%
PT rev (3m)-0.38%
EPS NQ rev (1m)-49.27%
EPS NQ rev (3m)-49.27%
EPS NY rev (1m)-9.64%
EPS NY rev (3m)-9.64%
Revenue NQ rev (1m)-83.1%
Revenue NQ rev (3m)-83.1%
Revenue NY rev (1m)-96.53%
Revenue NY rev (3m)-97.63%
Valuation
Industry RankSector Rank
PE 6.59
Fwd PE N/A
P/S 0.97
P/FCF 2.23
P/OCF 2.2
P/B 0.78
P/tB 0.78
EV/EBITDA -0.74
EPS(TTM)1.82
EY15.17%
EPS(NY)-3.62
Fwd EYN/A
FCF(TTM)5.37
FCFY44.77%
OCF(TTM)5.45
OCFY45.43%
SpS12.38
BVpS15.37
TBVpS15.37
PEG (NY)N/A
PEG (5Y)N/A
Graham Number25.09
Profitability
Industry RankSector Rank
ROA 25.74%
ROE 28.7%
ROCE 21.27%
ROIC 16.81%
ROICexc 176.8%
ROICexgc 176.8%
OM 27.69%
PM (TTM) 35.65%
GM N/A
FCFM 43.41%
ROA(3y)-15.34%
ROA(5y)-20.63%
ROE(3y)-16.71%
ROE(5y)-22.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 102.78%
Cap/Sales 0.64%
Interest Coverage 250
Cash Conversion 155.63%
Profit Quality 121.77%
Current Ratio 15.45
Quick Ratio 15.45
Altman-Z 4.5
F-Score8
WACC9.21%
ROIC/WACC1.82
Cap/Depr(3y)187.41%
Cap/Depr(5y)203.15%
Cap/Sales(3y)562.27%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)136.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.56%
EPS Next Y-299.03%
EPS Next 2Y-105.12%
EPS Next 3Y-51.27%
EPS Next 5Y-27.32%
Revenue 1Y (TTM)6774.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-87.34%
Revenue Next Year-99.86%
Revenue Next 2Y-89.36%
Revenue Next 3Y-45.98%
Revenue Next 5Y-13.01%
EBIT growth 1Y132.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-257.98%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y165.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y166.83%
OCF growth 3YN/A
OCF growth 5YN/A

KEROS THERAPEUTICS INC / KROS Fundamental Analysis FAQ

What is the fundamental rating for KROS stock?

ChartMill assigns a fundamental rating of 5 / 10 to KROS.


What is the valuation status for KROS stock?

ChartMill assigns a valuation rating of 4 / 10 to KEROS THERAPEUTICS INC (KROS). This can be considered as Fairly Valued.


How profitable is KEROS THERAPEUTICS INC (KROS) stock?

KEROS THERAPEUTICS INC (KROS) has a profitability rating of 4 / 10.


What are the PE and PB ratios of KEROS THERAPEUTICS INC (KROS) stock?

The Price/Earnings (PE) ratio for KEROS THERAPEUTICS INC (KROS) is 6.59 and the Price/Book (PB) ratio is 0.78.


Can you provide the financial health for KROS stock?

The financial health rating of KEROS THERAPEUTICS INC (KROS) is 10 / 10.